Go to content

Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases

Zorginstituut Nederland has carried out an assessment of the medicinal product hydrocortisone sodium phosphate (Softacor®) can be included in the Medicine Reimbursement System (GVS). The Ministry requested a marginal assessment.
Softacor® is an ocular corticosteroid registered for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases.

Download "Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases"

PDF document | 5 pages | 95 kB

Report | 06-08-2018

Advice

Based on the criteria for interchangeability, the conclusion can be drawn that hydrocortisone sodium phosphate (Softacor®) is interchangeable with other drugs in GVS cluster 0S01BABG. This cluster includes: prednisolone (Minims prednisolone di-sodium phosphate) and dexamethasone (Monofree dexamethasone). These two are also ocular corticosteroids, specifically eye-drops without preservatives for the treatment of, among other things, allergic conjunctivitis.
This fulfils the criterion for marginal assessment that the cluster must include at least two products; the said products are structural analogues.
We advise the Minister to place Softacor® on List 1A of the GVS in cluster 0S01BABG.

This report is a summary of recommendations by Zorginstituut Nederland. The original text of this excerpt is in Dutch.